PetMed Express, Inc. $PETS Shares Sold by Invesco Ltd.

Invesco Ltd. lowered its holdings in PetMed Express, Inc. (NASDAQ:PETS) by 22.8% during the first quarter, HoldingsChannel.com reports. The fund owned 114,867 shares of the company’s stock after selling 33,946 shares during the period. Invesco Ltd.’s holdings in PetMed Express were worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in shares of PetMed Express by 2.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 216,812 shares of the company’s stock worth $1,045,000 after acquiring an additional 4,410 shares during the period. Squarepoint Ops LLC raised its holdings in PetMed Express by 41.4% during the fourth quarter. Squarepoint Ops LLC now owns 17,686 shares of the company’s stock worth $85,000 after purchasing an additional 5,180 shares in the last quarter. Northern Trust Corp raised its holdings in PetMed Express by 13.2% during the fourth quarter. Northern Trust Corp now owns 51,116 shares of the company’s stock worth $246,000 after purchasing an additional 5,953 shares in the last quarter. Man Group plc raised its holdings in PetMed Express by 5.5% during the fourth quarter. Man Group plc now owns 145,796 shares of the company’s stock worth $703,000 after purchasing an additional 7,646 shares in the last quarter. Finally, Occudo Quantitative Strategies LP raised its holdings in PetMed Express by 70.0% during the fourth quarter. Occudo Quantitative Strategies LP now owns 38,597 shares of the company’s stock worth $186,000 after purchasing an additional 15,894 shares in the last quarter. Institutional investors own 73.33% of the company’s stock.

Insider Buying and Selling at PetMed Express

In related news, major shareholder Silvercape Investments Ltd acquired 118,200 shares of the company’s stock in a transaction on Friday, August 1st. The shares were purchased at an average price of $3.21 per share, for a total transaction of $379,422.00. Following the purchase, the insider owned 2,478,696 shares in the company, valued at $7,956,614.16. This represents a 5.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders bought 271,283 shares of company stock valued at $865,256. 1.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised PetMed Express from a “sell” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, PetMed Express presently has an average rating of “Sell” and an average target price of $3.20.

PetMed Express Price Performance

PETS stock opened at $3.05 on Friday. PetMed Express, Inc. has a 12 month low of $2.81 and a 12 month high of $6.85. The firm has a market cap of $63.00 million, a PE ratio of 305.31 and a beta of 0.77. The firm has a 50 day simple moving average of $3.23 and a 200 day simple moving average of $3.57.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.